Hemab Therapeutics Holdings Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
COAG
- Share Price
-
$40.83
- (As of Friday Closing)
Hemab Therapeutics Holdings General Information
Description
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Contact Information
Website
www.hemab.comCorporate Office
- 101 Main Street
- Suite 1220
- Cambridge, MA 02142
- United States
Corporate Office
- 101 Main Street
- Suite 1220
- Cambridge, MA 02142
- United States
Hemab Therapeutics Holdings Timeline
Hemab Therapeutics Holdings Stock Performance
As of 13-Nov-2026, Hemab Therapeutics Holdings’s stock price is $40.83. Its current market cap is $1.91B with 46.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $40.83 | $39.38 | $23.00 - $55.42 | $1.91B | 46.7M | 488K | -$3.55 |
Hemab Therapeutics Holdings Financials Summary
As of 30-Sep-2026, Hemab Therapeutics Holdings has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 984,168 | |||
| Revenue | 0 | 0 | 0 | |
| EBITDA | (100,924) | (65,810) | (52,014) | |
| Net Income | (93,474) | (63,913) | (48,707) | |
| Total Assets | 442,712 | 194,783 | 96,278 | 142,204 |
| Total Debt | 965 | 1,220 | 1,725 |
Hemab Therapeutics Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hemab Therapeutics Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Hemab Therapeutics Holdings Comparisons
Industry
Financing
Details
Hemab Therapeutics Holdings Competitors (2)
One of Hemab Therapeutics Holdings’s 2 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Spark Therapeutics | Formerly VC-backed | Philadelphia, PA |
Hemab Therapeutics Holdings Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hemab Therapeutics Holdings Patents
Hemab Therapeutics Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026176399-A1 | Rna inhibitors of alpha-2-antiplasmin, compositions, and methods of use thereof | Pending | 21-Feb-2025 | ||
| WO-2026176370-A1 | Methods of treating blood disorders | Pending | 19-Feb-2025 | ||
| WO-2026133296-A1 | Peptide inhibitors of fibrinolysis, methods, and uses thereof | Pending | 20-Dec-2024 | ||
| AU-2025218962-A1 | Methods of treating coagulopathy | Pending | 08-Feb-2024 | ||
| WO-2025168826-A1 | Methods of treating coagulopathy | Pending | 08-Feb-2024 | C07K16/2803 |
Hemab Therapeutics Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hemab Therapeutics Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hemab Therapeutics Holdings FAQs
-
When was Hemab Therapeutics Holdings founded?
Hemab Therapeutics Holdings was founded in 2019.
-
Where is Hemab Therapeutics Holdings headquartered?
Hemab Therapeutics Holdings is headquartered in Cambridge, MA.
-
What is the size of Hemab Therapeutics Holdings?
Hemab Therapeutics Holdings has 72 total employees.
-
What industry is Hemab Therapeutics Holdings in?
Hemab Therapeutics Holdings’s primary industry is Holding Companies.
-
Is Hemab Therapeutics Holdings a private or public company?
Hemab Therapeutics Holdings is a Public company.
-
What is Hemab Therapeutics Holdings’s stock symbol?
The ticker symbol for Hemab Therapeutics Holdings is COAG.
-
What is the current stock price of Hemab Therapeutics Holdings?
As of 13-Nov-2026 the stock price of Hemab Therapeutics Holdings is $40.83.
-
What is the current market cap of Hemab Therapeutics Holdings?
The current market capitalization of Hemab Therapeutics Holdings is $1.91B.
-
Who are Hemab Therapeutics Holdings’s competitors?
uniQure and Spark Therapeutics are competitors of Hemab Therapeutics Holdings.
-
What is Hemab Therapeutics Holdings’s annual earnings per share (EPS)?
Hemab Therapeutics Holdings’s EPS for 12 months was -$3.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
